Press Releases

Antibody Drug Conjugates Contract Manufacturing Market Growth at a CAGR of 16.8% from 2021 to 2030

Share This Article

The Antibody Drug Conjugates Contract Manufacturing market is projected to reach US$ 28.4 Bn by 2030. And registering a CAGR of around 16.8% over the forecast period 2021 – 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38541

Growth Factors

 The factors driving market expansion is complex nature of Antibody Drug Conjugates (ADCs), increasing demand for manufacturing capacity as well as increasing number of research on antibody therapies.

The coronavirus pandemic has assessed a typically optimistic and deliberate approach to development and disrupting supply chains not only for those antibodies deemed most promising a year ago, but also for others antibody drug conjugate that have been thrust into the spotlight as potential COVID-19 treatments.

Report Coverage

Report Scope Details
Market Size USD 28.4 billion by 2030
Growth Rate CAGR of 16.8% From 2021 to 2030
Base Year 2020
Historic Data 2017 to 2020
Forecast Period 2021 to 2030
Segments Covered Condition, Linker
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned Cambrex; ReciPharm; ThermoFisher; Pantheon; Corden Pharma; Samsung Biologics; Lonza; Catalent; Siegfried; Piramal Pharma Solutions; Boehringer Ingelheim

Report Highlights

The myeloma segment dominated the market and accounted for the largest revenue share of 59.4% in 2020. The factors that influence market growth are antibody drug conjugates, which is a novel type of treatment for myeloma patients that deliver a powerful cytotoxic chemical directly to the myeloma cell.

The cleavable linker segment dominated the market for ADC contract manufacturing and accounted for the largest revenue share of 66.5% in 2020. The segment is likely to remain dominant in the coming future. Major factor that influences the growth in the segment is the advantages that cleavable linkers take in certain circumstances to deliver the medication to the target cell.

The non-cleavable linker segment is projected to witness the fastest CAGR of 22.5% over the forecast period. ADCs with non-cleavable linkers are more reliant on the target cells’ biology. Non-cleavable linkers have higher plasma stability than cleavable linkers, which can help to enhance the therapeutic index.

Asia Pacific dominated the ADC contract manufacturing market and accounted for the largest revenue share of 56.4% in 2020. The region is projected to witness the fastest growth rate of 14.6% over the forecast period.

Key Players

  • Samsung Biologics
  • Lonza
  • Catalent
  • Siegfried
  • Piramal Pharma Solutions
  • Boehringer Ingelheim

Market Segmentation

  • Condition
    • Myeloma
    • Lymphoma
    • Breast Cancer
    • Others (Urothelial Cancer)
  • Linker
    • Cleavable Linker
    • Non-cleavable Linker
  • Regional
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Italy
      • Spain
    • Asia Pacific
      • Japan
      • China
      • India
      • Australia
      • South Korea
    • Latin America
      • Brazil
      • Mexico
      • Argentina
    • Middle East and Africa (MEA)
      • South Africa
      • Saudi Arabia
      • UAE

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38541

Reasons to Purchase this Report:

– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Antibody Drug Conjugates Contract Manufacturing Market, By Condition

7.1.  Antibody Drug Conjugates Contract Manufacturing Market, by Condition, 2021-2030

7.1.1.    Myeloma

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Lymphoma

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Breast Cancer

7.1.3.1.        Market Revenue and Forecast (2017-2030)

7.1.4.    Others (Urothelial Cancer)

7.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Antibody Drug Conjugates Contract Manufacturing Market, By Linker

8.1.  Antibody Drug Conjugates Contract Manufacturing Market, by Linker, 2021-2030

8.1.1.    Cleavable Linker

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Non-cleavable Linker

8.1.2.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Antibody Drug Conjugates Contract Manufacturing Market, Regional Estimates and Trend Forecast

9.1.  North America

9.1.1.    Market Revenue and Forecast, by Condition (2017-2030)

9.1.2.    Market Revenue and Forecast, by Linker (2017-2030)

9.1.3.    U.S.

9.1.3.1.        Market Revenue and Forecast, by Condition (2017-2030)

9.1.3.2.        Market Revenue and Forecast, by Linker (2017-2030)

9.1.4.    Rest of North America

9.1.4.1.        Market Revenue and Forecast, by Condition (2017-2030)

9.1.4.2.        Market Revenue and Forecast, by Linker (2017-2030)

9.2.  Europe

9.2.1.    Market Revenue and Forecast, by Condition (2017-2030)

9.2.2.    Market Revenue and Forecast, by Linker (2017-2030)

9.2.3.    UK

9.2.3.1.        Market Revenue and Forecast, by Condition (2017-2030)

9.2.3.2.        Market Revenue and Forecast, by Linker (2017-2030)

9.2.4.    Germany

9.2.4.1.        Market Revenue and Forecast, by Condition (2017-2030)

9.2.4.2.        Market Revenue and Forecast, by Linker (2017-2030)

9.2.5.    France

9.2.5.1.        Market Revenue and Forecast, by Condition (2017-2030)

9.2.5.2.        Market Revenue and Forecast, by Linker (2017-2030)

9.2.6.    Rest of Europe

9.2.6.1.        Market Revenue and Forecast, by Condition (2017-2030)

9.2.6.2.        Market Revenue and Forecast, by Linker (2017-2030)

9.3.  APAC

9.3.1.    Market Revenue and Forecast, by Condition (2017-2030)

9.3.2.    Market Revenue and Forecast, by Linker (2017-2030)

9.3.3.    India

9.3.3.1.        Market Revenue and Forecast, by Condition (2017-2030)

9.3.3.2.        Market Revenue and Forecast, by Linker (2017-2030)

9.3.4.    China

9.3.4.1.        Market Revenue and Forecast, by Condition (2017-2030)

9.3.4.2.        Market Revenue and Forecast, by Linker (2017-2030)

9.3.5.    Japan

9.3.5.1.        Market Revenue and Forecast, by Condition (2017-2030)

9.3.5.2.        Market Revenue and Forecast, by Linker (2017-2030)

9.3.6.    Rest of APAC

9.3.6.1.        Market Revenue and Forecast, by Condition (2017-2030)

9.3.6.2.        Market Revenue and Forecast, by Linker (2017-2030)

9.4.  MEA

9.4.1.    Market Revenue and Forecast, by Condition (2017-2030)

9.4.2.    Market Revenue and Forecast, by Linker (2017-2030)

9.4.3.    GCC

9.4.3.1.        Market Revenue and Forecast, by Condition (2017-2030)

9.4.3.2.        Market Revenue and Forecast, by Linker (2017-2030)

9.4.4.    North Africa

9.4.4.1.        Market Revenue and Forecast, by Condition (2017-2030)

9.4.4.2.        Market Revenue and Forecast, by Linker (2017-2030)

9.4.5.    South Africa

9.4.5.1.        Market Revenue and Forecast, by Condition (2017-2030)

9.4.5.2.        Market Revenue and Forecast, by Linker (2017-2030)

9.4.6.    Rest of MEA

9.4.6.1.        Market Revenue and Forecast, by Condition (2017-2030)

9.4.6.2.        Market Revenue and Forecast, by Linker (2017-2030)

9.5.  Latin America

9.5.1.    Market Revenue and Forecast, by Condition (2017-2030)

9.5.2.    Market Revenue and Forecast, by Linker (2017-2030)

9.5.3.    Brazil

9.5.3.1.        Market Revenue and Forecast, by Condition (2017-2030)

9.5.3.2.        Market Revenue and Forecast, by Linker (2017-2030)

9.5.4.    Rest of LATAM

9.5.4.1.        Market Revenue and Forecast, by Condition (2017-2030)

9.5.4.2.        Market Revenue and Forecast, by Linker (2017-2030)

Chapter 10.  Company Profiles

10.1.              Samsung Biologics

10.1.1.  Company Overview

10.1.2.  Condition Offerings

10.1.3.  Financial Performance

10.1.4.  Recent Initiatives

10.2.              Lonza

10.2.1.  Company Overview

10.2.2.  Condition Offerings

10.2.3.  Financial Performance

10.2.4.  Recent Initiatives

10.3.              Catalent

10.3.1.  Company Overview

10.3.2.  Condition Offerings

10.3.3.  Financial Performance

10.3.4.  Recent Initiatives

10.4.              Siegfried

10.4.1.  Company Overview

10.4.2.  Condition Offerings

10.4.3.  Financial Performance

10.4.4.  Recent Initiatives

10.5.              Piramal Pharma Solutions

10.5.1.  Company Overview

10.5.2.  Condition Offerings

10.5.3.  Financial Performance

10.5.4.  Recent Initiatives

10.6.              Boehringer Ingelheim

10.6.1.  Company Overview

10.6.2.  Condition Offerings

10.6.3.  Financial Performance

10.6.4.  Recent Initiatives

Chapter 11.  Research Methodology

11.1.              Primary Research

11.2.              Secondary Research

11.3.              Assumptions

Chapter 12.  Appendix

12.1.              About Us

Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38541

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com

Related Articles

Back to top button